查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886542

急性骨髓性白血病市場－全球產業規模、佔有率、趨勢、機會和預測，依化療、地區和競爭格局分類，2020-2030年預測

Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy, By Region, and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球急性骨髓性白血病市場規模為15.6億美元，預計到2030年將以8.90%的複合年成長率成長至26.3億美元。急性骨髓性白血病（AML）是一種快速進展的血液和骨髓癌症，其特徵是異常髓係原始細胞不受控制地增生。 AML治療市場的主要促進因素是該疾病在全球範圍內發病率的不斷上升，以及老年人口的成長，老年人面臨更高的診斷風險。

市場概覽
預測期 2026-2030
市場規模：2024年 15.6億美元
市場規模：2030年 26.3億美元
複合年成長率：2025-2030年 8.90%
成長最快的細分市場 荷爾蒙療法
最大的市場 北美洲

主要市場促進因素

全球急性骨髓性白血病市場主要受益於急性髓性白血病（AML）研究和治療技術的不斷進步。這些創新透過新型藥物和治療策略，拓展了治療選擇，並改善了患者的治療效果。

主要市場挑戰

先進治療方案的高昂成本嚴重阻礙了全球急性骨髓性白血病市場的成長。這些高額費用直接影響患者獲得可能挽救生命的治療的機會，從而限制了創新療法的整體普及率和收入潛力。

主要市場趨勢

口服和門診治療方案的日益普及，顯著重塑了全球急性骨髓性白血病市場，提高了患者的便利性，並減輕了醫院基礎設施的負擔。這些創新方法使得治療可以在限制較少的環境下進行，從而改善患者的生活品質，尤其是老年患者或合併其他疾病的患者。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球急性骨髓性白血病市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 化療（阿糖胞苷、蒽環類藥物、烷化劑、抗代謝藥、酪胺酸激酶抑制劑、荷爾蒙療法、其他化療藥物）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美急性骨髓性白血病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲急性骨髓性白血病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區急性骨髓性白血病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲急性骨髓性白血病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲急性骨髓性白血病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球急性骨髓性白血病市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Bristol-Myers Squibb Company (Celgene Corporation)
  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma
  • Oncolyze Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 24060

The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.56 Billion
Market Size 2030USD 2.63 Billion
CAGR 2025-20308.90%
Fastest Growing SegmentHormonal therapy
Largest MarketNorth America

Key Market Drivers

The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations.

Key Market Challenges

The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.

Key Market Trends

The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities.

Key Market Players

  • Bristol-Myers Squibb Company (Celgene Corporation)
  • Novartis AG
  • Genmab AS
  • Otsuka Holdings Co. Ltd
  • Sanofi-Aventis (Genzyme Corporation)
  • Teva Pharmaceutical (Cephalon Inc.)
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals Inc.
  • Astellas Pharma
  • Oncolyze Inc.

Report Scope:

In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Myeloid Leukemia Market, By Chemotherapy:

  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal therapy
  • Other chemotherapies

Acute Myeloid Leukemia Market, By Region:

  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.

Available Customizations:

Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Myeloid Leukemia Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal therapy, Other chemotherapies)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. North America Acute Myeloid Leukemia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Chemotherapy
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Acute Myeloid Leukemia Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Chemotherapy
    • 6.3.2. Canada Acute Myeloid Leukemia Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Chemotherapy
    • 6.3.3. Mexico Acute Myeloid Leukemia Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Chemotherapy

7. Europe Acute Myeloid Leukemia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Chemotherapy
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Acute Myeloid Leukemia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Chemotherapy
    • 7.3.2. France Acute Myeloid Leukemia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Chemotherapy
    • 7.3.3. United Kingdom Acute Myeloid Leukemia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Chemotherapy
    • 7.3.4. Italy Acute Myeloid Leukemia Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Chemotherapy
    • 7.3.5. Spain Acute Myeloid Leukemia Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Chemotherapy

8. Asia Pacific Acute Myeloid Leukemia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Chemotherapy
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Acute Myeloid Leukemia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Chemotherapy
    • 8.3.2. India Acute Myeloid Leukemia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Chemotherapy
    • 8.3.3. Japan Acute Myeloid Leukemia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Chemotherapy
    • 8.3.4. South Korea Acute Myeloid Leukemia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Chemotherapy
    • 8.3.5. Australia Acute Myeloid Leukemia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Chemotherapy

9. Middle East & Africa Acute Myeloid Leukemia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Chemotherapy
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Chemotherapy
    • 9.3.2. UAE Acute Myeloid Leukemia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Chemotherapy
    • 9.3.3. South Africa Acute Myeloid Leukemia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Chemotherapy

10. South America Acute Myeloid Leukemia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Chemotherapy
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Chemotherapy
    • 10.3.2. Colombia Acute Myeloid Leukemia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Chemotherapy
    • 10.3.3. Argentina Acute Myeloid Leukemia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Chemotherapy

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Acute Myeloid Leukemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb Company (Celgene Corporation)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Genmab AS
  • 15.4. Otsuka Holdings Co. Ltd
  • 15.5. Sanofi-Aventis (Genzyme Corporation)
  • 15.6. Teva Pharmaceutical (Cephalon Inc.)
  • 15.7. Pfizer Inc.
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Sunesis Pharmaceuticals Inc.
  • 15.10. Astellas Pharma
  • 15.11. Oncolyze Inc.

16. Strategic Recommendations

17. About Us & Disclaimer